Skip to main content
SpringerLink
Log in

Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity

  • Conference paper
Advances in Research on Neurodegeneration

Part of the book series: 6th International Winter Conference on N eurodegeneration ((NEURAL SUPPL,volume 55))

Summary

Apomorphine is a potent radical scavenger and iron chelator. In vitro apomorphine acts as a potent iron chelator and radical scavenger with IC50 of 0.3 μM for iron (2.5 μM) induced lipid peroxidation in rat brain mitochondrial preparation, and it inhibits mice striatal MAO-A and MAO-B activities with IC50 values of 93 μM and 241 μM. Apomorphine (1–10 μM) protects rat pheochromocytoma (PC12) cells from 6-hydroxydopamine (150 μM) and H2O2 (0.6 mM) induced cytotoxicity and cell death. The neuroprotective property of (R)-apomorphine, a dopamine D1-D2 receptor agonist, has been studied in the MPTP (N-methyl-4-pheny1-1, 2,3,6-tetrahydropyridine) model of Parkinson’s disease. (R)-apomorphine (5–10mg/kg, s.c.) pretreatment in C57BL mice, protects against MPTP (24mg/kg, I.P) induced loss of nigro-striatal dopamine neurons, as indicated by striatal dopamine content, tyrosine hydroxylase content and tyrosine hydroxylase activity. It is suggested that the neuroprotective effect of (R)-apomorphine against MPTP neurotoxicity derives from its radical scavenging and MAO inhibitory actions and not from its agonistic activity, since the mechanism of MPTP dopaminergic neurotoxicity involves the generation of oxygen radical species induced-oxidative stress.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  • Adamson GM, Billings RE (1993) Cytokine toxicity and induction of NO synthesis activity in cultured mouse hepatocytes. Toxicol Appl Pharmacol 119: 100–107.

    Article  PubMed  CAS  Google Scholar 

  • Ben-Shachar D, Youdim MBH (1991) Intranigral iron injection induces behavioral and biochemical “parkinsonism” in rats. J Neurochem 57: 2133–2135.

    Article  PubMed  CAS  Google Scholar 

  • Ben-Shachar D, Eshel G, Finberg JPM, Youdim MBH (1991) The iron chelator desferrioxamine (desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal neurons. J Neurochem 56: 1441–1444.

    Article  PubMed  CAS  Google Scholar 

  • Braughler JM, Pregenzer JF, Chase RL, Duncan LA, Jacobson EJ, McCall JM (1987) Novel 21-aminosteroids as potent inhibitors of iron-dependent lipid peroxidation. J Biol Chem 262: 10438–10440.

    PubMed  CAS  Google Scholar 

  • Cadet JL, Katz M, Jackson-Lewis V, Fahn S (1989) Vitamin E attenuates the toxic effects of intrastriatal injection of 6-hydroxydopamine (6-OHDA) in rats: behavioral and biochemical evidence. Brain Res 476: 5–10.

    Article  Google Scholar 

  • Cohen G, Werner P (1994) Free radicals oxidative stress and neurodegeneration. In: Calne DB (ed) Neurodegenerative disorders. Saunders, Philadelphia, pp 139–162.

    Google Scholar 

  • Colzi A, Turner K, Lee AJ (1998) Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson’s disease. J Neurol Neurosurg Psychiatry 64: 573–576.

    Article  PubMed  CAS  Google Scholar 

  • Di Monte D, Dandy MS, Smith MT (1987) Increase efflux rather than oxidation is the mechanism of glutathione dspletion by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Biochem Biophys Res Commun 148: 153–160.

    Article  Google Scholar 

  • Ebadi M, Srinivasan Sk, Baxi MD (1996) Oxidative stress and antioxidant therapy in Parkinson’s disease. Prog Neurobiol 48: 1–19.

    Article  PubMed  CAS  Google Scholar 

  • Gancher S (1995) Pharmacokinetics of apomorphine in Parkinson’s disease. J Neural Transm [Suppl] 45: 137–141.

    CAS  Google Scholar 

  • Gancher ST, Nutt JG, Woodward WR (1995) Apomorphine infusional therapy in Parkinson’s disease: clinical utility and lack of tolerance. Mov Disord 10: 37–43.

    Article  PubMed  CAS  Google Scholar 

  • Gassen M, Youdim MBH (1998) Free radical scavengers: chemical concepts and clinical relevance. J Neural Transm (In press).

    Google Scholar 

  • Gassen M, Glinka Y, Pinchasi B, Youdim MBH (1996) Apomorphine is highly potent free radical scavenger in rat mitochondrial fraction. Eur J Pharmacol 308: 219–225.

    Article  PubMed  CAS  Google Scholar 

  • Gassen M, Gross A, Youdim MBH (1998a) Apomorphine enantiomers protect pheochromocytoma (PC12) cells from oxidative stress induced by hydrogen peroxide and 6-hydroxydopamine. Mov Disord 13: 242–248.

    Article  PubMed  CAS  Google Scholar 

  • Gassen M, Pinchasi B, Youdim MBH (1998b) Apomorphine is a potent radical scavenger and protects culture pheochromocytoma cells from 6-OHDA and H2O2-induced cell death. Adv Pharmacol 42: 320–324.

    Article  PubMed  CAS  Google Scholar 

  • Gerlach M, Ben-Shachar D, Riederer P, Youdim MBH (1994) Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem 63: 793–806.

    Article  PubMed  CAS  Google Scholar 

  • Glinka Y, Youdim MBH (1995) Inhibition of mitochondrial complex I and IV by 6-hydroxydopamine. Euro J Pharmacol 292: 329–332.

    CAS  Google Scholar 

  • Glinka Y, Tipton KF, Youdim MBH (1996) Nature of inhibition of mitochondrial respiratory complex I by 6-hydroxydopamine. J Neurochem 66: 2004–2010.

    Article  PubMed  CAS  Google Scholar 

  • Glinka Y, Gassen M, Youdim MBH (1997) Mechanism of 6-hydroxydopamine neurotoxicity. J Neural Transm [Suppl] 50: 55–66.

    CAS  Google Scholar 

  • Greene LA, Aletta JM, Rukenstein A, Green SH (1987) PC12 pheocytoma cells, culture, nerve growth factor treatment and experimental exploitation. Methods Enzymol 147: 207–216.

    Article  PubMed  CAS  Google Scholar 

  • Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC (1984) Protection against the dopaminergic neurotoxicity of l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311: 467–469.

    Article  PubMed  CAS  Google Scholar 

  • Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MBH (1990) Brain iron and ferritin in Parkinson’s and Alzheimer’s diseases. J Neural Transm [PD Sect] 2: 327–340.

    Article  CAS  Google Scholar 

  • Jenner P, Olanow CW (1996) Pathological evidence for oxidative stress in Parkinson’s disease and related degenerative disorders. In: Olanow CW, Jenner P, Youdim MBH (eds) Neurodegeneration and neuroprotection in Parkinson’s disease. Academic Press, London, pp 24–45.

    Google Scholar 

  • Kato T, Horiuchi S, Togari A, Nagatsu T (1981) A sensitive and inexpensive highperformance liquid Chromatographic assay for tyrosine hydroxylase. Experientia 37: 809–811.

    Article  PubMed  CAS  Google Scholar 

  • Lan J, Jiang DH (1997) Desferrioxamine and vitamin E protect aginst iron and MPTP-induced neurodegeneration in mice. J Neural Transm 104: 469–481.

    Article  PubMed  CAS  Google Scholar 

  • Lees AJ (1993) Dopamine agonists in Parkinson’s disease: a look at apomorphine. Fundam Clin Pharmacol 7: 121–128.

    Article  PubMed  CAS  Google Scholar 

  • LeWitt PA (1994) Clinical trials of neuroprotection in Parkinson’s disease: long-term Selegiline and alpha-tocopherol treatment. J Neural Transm [Suppl] 43: 171–181.

    CAS  Google Scholar 

  • Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MBH (1996) Dopamine, 6-hydroxydopamine, iron, and dioxygen-their mutual interactions and possible implication in the development of Parkinson’s disease. Biochem Biophys Acta 1316: 160–168.

    PubMed  Google Scholar 

  • Liu J, Mori A (1993) Monoamine metabolism provides an antioxidant defense in the brain against oxidant-and free radical-induced damage. Arch Biochem Biophys 302: 118–127.

    Article  PubMed  CAS  Google Scholar 

  • Matthews RT, Yang L, Beal M (1997) S-Methylthiocitrulline, a neuronal nitric oxide synthase inhibitor, protects against malonate and MPTP neurotoxicity. Exp Neurol 143: 282–286.

    Article  PubMed  CAS  Google Scholar 

  • Mochizuki H, Imai H, Endo K, Yokomizo K, Murata Y, Hattori N, Mizuno Y (1994) Iron accumulation in the substantia nigra of l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced hemiparkinsonism in monkeys. Neurosci Lett 168: 251–253.

    Article  PubMed  CAS  Google Scholar 

  • Monteiro HP, Winterbourn CC (1989) 6-Hydroxydopamine releases iron from ferritin and promotes ferritin-dependent lipid peroxidation. Biochem Pharmacol 38: 4177–4182.

    Article  PubMed  CAS  Google Scholar 

  • O’Carroll AM, Fowler CJ, Phillips JP, Tobbia I, Tipton KF (1983) The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions. Naunyn Schmiedebergs Arch Pharmacol 322: 198–202.

    Article  PubMed  Google Scholar 

  • Oestreicher E, Sengstock GJ, Riederer P, Olanow CW, Dunn AJ, Arendash GW (1994) Degeneration of nigrostriatal dopaminergic neurons increases iron within the substantia nigra: a histochemical and neurochemical study. Brain Res 660: 8–18.

    Article  PubMed  CAS  Google Scholar 

  • Olanow CW (1993) A scientific rationale for protective therapy in Parkinson’s disease. J Neural Transm [Gen. Sect] 91: 161–180.

    Article  CAS  Google Scholar 

  • Olanow CW, Youdim MBH (1996) Iron and neurodegeneration: Prospects for neuroprotection. In: Olanow CW, Jenner P, Youdim MBH (eds) Neurodegeneration and neuroprotection in Parkinson’s disease. Academic Press, New York, pp 50–67.

    Google Scholar 

  • Perumal AS, Gopal VB, Tordzro WK, Cooper TB, Cadet JL (1992) Vitamin E attenuates the toxic effects of 6-hydroxydopamine on free radical scavenging systems in rat brain. Brain Res Bull 29: 699–701.

    Article  PubMed  CAS  Google Scholar 

  • Przuntek H (1994) Clinical aspects of neuroprotection in Parkinson’s disease. J Neural Transm [Suppl] 43: 163–169.

    CAS  Google Scholar 

  • Rogers JT, Bridges KR, Durmowicz GP, Glass J, Zuron PE, Munro HN (1990) Translational control during the acute phase response. Ferritin synthesis in response to interleukin-1. J Biol Chem 265: 14572–14578.

    PubMed  CAS  Google Scholar 

  • Sam EE, Verbeke N (1995) Free radical scavenging properties of apomorphine enantiomers and dopamine — possible implication in their mechanism of action in parkinsonism. J Neural Transm [PD Sect] 10: 115–127.

    Article  CAS  Google Scholar 

  • Sam E, Jeanjean AP, Maloteaux JM, Verbeke N (1995) Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application. Eur J Drug Metab Parmacokinet 20: 27–33.

    Article  CAS  Google Scholar 

  • Santiago M, Matarredona ER, Granero L, Cano J, Machado A (1997) Neuroprotective effect of the iron chelator desferrioxamine against MPP+ toxicity on striatal dopaminergic terminals. J Neurochem 68: 732–738.

    Article  PubMed  CAS  Google Scholar 

  • Seiser C, Teixeira S, Kuhn LC (1993) Interleukin-2 dependent transcriptional and posttranscriptional regulation of transferrin receptor mRNA, J Biol Chem 268: 13074–13080.

    PubMed  CAS  Google Scholar 

  • Sengstock GJ, Olanow CW, Dunn AJ, Barone S Jr, Arendash GW (1994) Progressive changes in striatal dopaminergic markers, nigral volume, and rotational behavior following iron infusion into the rat substantia nigra. Exp Neurol 130: 82–94.

    Article  PubMed  CAS  Google Scholar 

  • Simeonova PP, Luster MI (1995) Iron and reactive oxygen species in the asbestos-induced tumor necrosis factor-alpha response from alveolar macrophages. Am J Respir Cell Mol Biol 12: 676–683.

    PubMed  CAS  Google Scholar 

  • Singer TP, Castagnoli N Jr, Ramsay RR, Treor AJ (1987) Biochemical events in the development of parkinsonism induced by l-methyl-4-phenyl-l,2,3,6-tetrahydropyridine. J Neurochem 49: 1–8.

    Article  PubMed  CAS  Google Scholar 

  • Sorrenti V, Di Giacomo C, Renis M, Russo A, La Delfa C, Perez-Polo JR, Vanella A (1994) Lipid peroxidation and survival in rats following cerebral post-ischemic reperfusion: effect of drugs with different molecular mechanisms. Drugs Exp Clin Res 20: 185–189.

    PubMed  CAS  Google Scholar 

  • Stadtman ER (1993) Oxidation of free amino acids and amino acid residues in proteins by radiolysis and by metal-catalyzed reactions. Annu Rev Biochem 62: 797–821.

    Article  PubMed  CAS  Google Scholar 

  • Temlett JA, Landsberg JP, Watt F, Grime GW (1994) Increased iron in the substantia nigra compacta of the MPTP-lesioned hemiparkinsonian african green monkey: evidence from proton microprobe element microanalysis. J Neurochem 62: 134–146.

    Article  PubMed  CAS  Google Scholar 

  • Vimard F, Nouvelot A, Duval D (1996) Cytotoxic effects of oxidative stress on neuronallike pheochromocytoma cells. Biochem Pharmacol 51: 1389–1395.

    Article  PubMed  CAS  Google Scholar 

  • Youdim MBH, Ben-Shachar D, Riederer P (1990) The role of monoamine oxidase, ironmelanin interaction, and intracellular calcium in Parkinson’s disease. J Neural Transm [Suppl] 32: 239–248.

    CAS  Google Scholar 

  • Youdim MBH, Ben-Shachar D, Riederer P (1993) The possible role of iron in the etiopathology of Parkinson’s disease. Mov Disord 8: 1–12.

    Article  PubMed  CAS  Google Scholar 

  • Zhao W, Richardson JS, Mombourquette MJ, Weil JA (1995) An in vitro EPR study of the free-radical scavenging action of the lazaroid antioxidants U-74500A and U-78517F. Free Radic Biol Med 19: 21–30.

    Article  PubMed  CAS  Google Scholar 

  • Zigmond MJ, Berger TW, Grace AA, Stricker EM (1989) Compensatory responses to nigrostriatal bundle injury. Mol Chem Neuropathol 10: 185–200.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Bruce Rappaport Family Research Institute and Department of Pharmacology, Technion — Faculty of Medicine, Eve Topf and U.S. National Parkinson’s Foundation Centers for Neurodegenerative Diseases, Haifa, Israel

    E. Grünblatt, S. Mandel & Prof. M. B. H. Youdim

  2. Merck KGaA, Biomedical Research CNS, Darmstadt, Federal Republic of Germany

    M. Gassen

  3. N.I.H. Fogarty International Center and NIMH, Bethesda, MD, USA

    Prof. M. B. H. Youdim

Authors
  1. E. Grünblatt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Mandel
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Gassen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. M. B. H. Youdim
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinik für Neurologie, Innsbruck, Österreich

    W. Poewe  & G. Ransmayr  & 

Rights and permissions

Reprints and permissions

Copyright information

© 1999 Springer-Verlag/Wien

About this paper

Cite this paper

Grünblatt, E., Mandel, S., Gassen, M., Youdim, M.B.H. (1999). Potent neuroprotective and antioxidant activity of apomorphine in MPTP and 6-hydroxydopamine induced neurotoxicity. In: Poewe, W., Ransmayr, G. (eds) Advances in Research on Neurodegeneration. 6th International Winter Conference on N eurodegeneration, vol 55. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6369-6_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-7091-6369-6_6

  • Publisher Name: Springer, Vienna

  • Print ISBN: 978-3-211-83261-5

  • Online ISBN: 978-3-7091-6369-6

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation